Skip to main content
. Author manuscript; available in PMC: 2016 Aug 15.
Published in final edited form as: J Immunol. 2015 Jul 15;195(4):1665–1675. doi: 10.4049/jimmunol.1500457

Figure 2.

Figure 2

IL2-anti-IL2 immune complex treatment is not sufficient to rescue the blunted recall response. (A) CFSEdimCD25+ % of NR23.4 cells in the spleen are shown. (B) Mice were infected i.v. with C. trachomatis, treated with IL2-anti-IL2 immune complex (IL2 IC) or isotype control antibodies on days 3 and 5 p.i. (early) or on days 24 and 26 p.i. (late), and re-challenged with VacCrpA on day 28 p.i. CrpA-specific CD8+ T cell numbers 5 days after secondary challenge are shown. Representative data from two experiments are shown, each with 5–7 mice per group.